Exogenesis Corporation is a privately-held, venture capital backed company focused on the commercialization of proprietary surface modification and control technology which i) improves the safety and performance of implantable drug delivery devices and ii) enables enhanced integration, healing and performance of vascular, dental and orthopedic implants.

The Company’s core technology is called Gas Cluster Ion Beam (GCIB) processing. GCIB has ability to produce a range of important atomic level surface modification effects. While there are many ways to modify surfaces, GCIB is unique and fundamentally superior for many applications.

GCIB, a commercially proven and validated technology, was originally developed to provide nano-scale surface processing for semiconductors and opto-electronic devices. The GCIB concept originated during the early 1990’s in Japan at the Ion Beam Engineering Experimental Laboratory of Kyoto University under the direction of Professor Isao Yamada.

Exogenesis is developing GCIB for several large market opportunities including: i) safer and more precisely controlled implantable drug delivery devices (such as stents), ii) implants that more rapidly integrate into adjoining bone thus promoting healing (e.g., dental and orthopedic implants), iii) ligaments, tendons and other soft tissue implants that more fully remodel thus promoting healing and iv) safer metal hip and other load bearing orthopedic implants with significantly reduced wear particle burden.

Exogenesis has exclusive worldwide rights to core GCIB intellectual property for biomedical applications. The Company owns or holds exclusive license to more than 30 issued United States Patents and 15 Patent Applications in addition to 30 distinct PCT cases pending in countries outside of the United States.

Exogenesis is engaged in development activities with a number of partners in the medical device industry and is interested in exploring new applications for its technology with other firms who are seeking to develop new medical devices with improved safety and / or efficacy features.